Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi | AfterMarkets
Biogen’s shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.
https://www.marketbeat.com/original...fter-fda-approval-of-alzheimers-drug-leqembi/
- Biogen showed the biggest percentage decline within the healthcare sector on July 7, as Wall Street fretted about possible roadblocks to its new drug's launch.
- Leqembi has shown a modest ability to slow cognitive decline in early-stage Alzheimer's patients.
- The FDA expressed concerns about potential side effects and called for additional monitoring and scans for higher-risk patients.
- Implementing these additional steps may pose logistical challenges for doctors and clinics, potentially impacting prescriptions.
Biogen’s shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.
https://www.marketbeat.com/original...fter-fda-approval-of-alzheimers-drug-leqembi/
- Biogen showed the biggest percentage decline within the healthcare sector on July 7, as Wall Street fretted about possible roadblocks to its new drug's launch.
- Leqembi has shown a modest ability to slow cognitive decline in early-stage Alzheimer's patients.
- The FDA expressed concerns about potential side effects and called for additional monitoring and scans for higher-risk patients.
- Implementing these additional steps may pose logistical challenges for doctors and clinics, potentially impacting prescriptions.